新型HLA-DPA1*01:12:03等位基因的特征通过基于测序的类型化
Marine Cargou1, Marco Andreani2, Mariarosa Battarra2
1CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.
HLA
|September 5, 2024
概括
一种新的人类白细胞抗原DPA1变体,HLA-DPA1*01:12:03,已经被确定. 这种新的HLA-DPA1等位基因因与已知的等位基因有单个核酸替代的差异.
科学领域:
- 免疫遗传学 免疫遗传学
- 分子生物学分子生物学
背景情况:
- 人类白细胞抗原 (HLA) 基因对免疫反应至关重要.
- 在HLA等位基因的遗传变异可以影响免疫系统的功能和疾病易感性.
研究的目的:
- 为了表征一种新发现的HLA-DPA1等位基因.
- 描述这种新等位基因与以前已知的等位基因之间的特定遗传差异.
主要方法:
- 在HLA-DPA1基因的核酸测序.
- 对DNA序列进行比较分析以确定变异.
主要成果:
- 一个新的HLA-DPA1等位基因被确定,被指定为HLA-DPA1*01:12:03.
- 这种等位基因与HLA-DPA1*01:12:01有单个核酸替代的差异.
- 替代位于该基因的第4个外显子内的第204个代码子.
结论:
- 鉴定HLA-DPA1*01:12:03扩大了已知的HLA-DPA1等位基因的范围.
- 这种特定的核酸变化可能对HLA类型和免疫学研究产生影响.
关键词:
哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01:12:03 HLA-DPA1*01*01:12:03 这是一个很大的问题一个新型的等位基因基于序列化的类型化.相关概念视频
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


